Home » Stocks » Aptevo Therapeutics

Aptevo Therapeutics Inc. (APVO)

Stock Price: $8.09 USD -0.31 (-3.69%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 26.15M
Revenue (ttm) 32.42M
Net Income (ttm) -25.53M
Shares Out 3.23M
EPS (ttm) -7.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $8.09
Previous Close $8.40
Change ($) -0.31
Change (%) -3.69%
Day's Open 8.38
Day's Range 8.07 - 8.44
Day's Volume 134,565
52-Week Range 2.94 - 14.28

More Stats

Market Cap 26.15M
Enterprise Value 14.47M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 3.23M
Float 2.41M
EPS (basic) -7.93
EPS (diluted) -7.64
FCF / Share -12.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 193,600
Short Ratio 0.03
Short % of Float 1.61%
Beta 2.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.81
PB Ratio 1.83
Revenue 32.42M
Operating Income -39.21M
Net Income -25.53M
Free Cash Flow -39.71M
Net Cash 11.69M
Net Cash / Share 3.62
Gross Margin -53.23%
Operating Margin -120.94%
Profit Margin -100.50%
FCF Margin -122.48%
ROA -46.02%
ROE -158.28%
ROIC -165.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$32.33*
(299.63% upside)
Low
24.0
Current: $8.09
High
42.0
Target: 32.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue32.4223.0714.669.9933.6045.630.17
Revenue Growth40.56%57.37%46.8%-70.28%-26.36%26741.76%-
Gross Profit12.5011.859.65-2.4816.6729.380.17
Operating Income-42.60-51.67-53.95-139-61.10-51.71-53.34
Net Income-40.45-53.696.97-112-59.32-51.12-53.34
Shares Outstanding2.921.611.521.451.45--
Earnings Per Share-13.86-33.464.62-77.70-41.02--
Operating Cash Flow-42.38-51.42-41.57-36.86-48.76-47.01-51.39
Capital Expenditures-0.15-0.98-1.40-2.51-1.53-0.99-1.02
Free Cash Flow-42.54-52.40-42.98-39.37-50.29-48.00-52.41
Cash & Equivalents19.9530.6481.1854.934.643.590.00
Total Debt23.1919.2819.0618.38---
Net Cash / Debt-3.2411.3662.1236.544.643.590.00
Assets53.4167.4911791.86128120-
Liabilities41.5737.0934.9741.2939.1525.36-
Book Value11.8430.4182.0450.5788.6294.61-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aptevo Therapeutics Inc.
Country United States
Employees 80
CEO Marvin L. White

Stock Information

Ticker Symbol APVO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APVO

Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.